[December 19, 2014] |
|
Research and Markets: Diabetic Neuropathic Pain - Pipeline Review, H2 2014
Research and Markets (http://www.researchandmarkets.com/research/kws5ld/diabetic)
has announced the addition of the "Diabetic
Neuropathic Pain - Pipeline Review, H2 2014" report to their
offering.
This report provides comprehensive information on the therapeutic
development for Diabetic Neuropathic Pain, complete with comparative
analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for
Diabetic Neuropathic Pain and special features on late-stage and
discontinued projects.
Drug profiles/records featured in the report undergoes periodic updation
following a stringent set of processes that ensures that all the
profiles are updated with the latest set of information. Additionally,
processes including live news & deas tracking, browser based alert-box
and clinical trials registries tracking ensure that the most recent
developments are captured on a real time basis.
Reasons to buy
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Identify and understand important and diverse types of therapeutics
under development for Diabetic Neuropathic Pain
-
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
-
Devise corrective measures for pipeline projects by understanding
Diabetic Neuropathic Pain pipeline depth and focus of Indication
therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Companies Mentioned:
-
Bristol-Myers Squibb Company
-
AstraZeneca
-
Eli Lilly and Company
-
BioDelivery Sciences
-
Daiichi Sankyo
-
Acorda Therapeutics
-
Astellas Pharma
-
Glenmark Pharmaceuticals
-
KunWha Pharmaceutical
-
Mertiva
-
Grunenthal
-
Kyorin Pharmaceutical
-
Bial
-
Lohocla Research
-
Relmada Therapeutics
-
Sphaera Pharma
-
Immune Pharmaceuticals
-
AbbVie
-
Dong-A Socio Group
For more information visit http://www.researchandmarkets.com/research/kws5ld/diabetic
[ Back To TMCnet.com's Homepage ]
|